Study suggests once-daily prednisolone may reduce PU/PD in dogs: full analysis

A new canine crossover study published in the Journal of Small Animal Practice suggests that once-daily oral prednisolone may cause less excessive drinking than the same daily dose split into twice-daily administration. In 12 dogs, investigators found significantly lower water intake by day 14 with once-daily dosing, while urine osmolality and urine specific gravity did not differ between the two regimens. That matters because polyuria and polydipsia are among the most common and most disruptive adverse effects pet parents report during glucocorticoid treatment. (researchgate.net)

The question behind the study is a familiar one in small animal practice: does dividing a steroid dose make treatment easier for dogs to tolerate? Prednisolone remains a mainstay across inflammatory and immune-mediated conditions, but PU/PD can quickly affect household routines, continence, sleep, and adherence. General veterinary references define polydipsia in dogs as water intake above roughly 100 mL/kg/day, underscoring why even modest shifts in intake can matter clinically. (veterinarypartner.vin.com)

According to the study abstract, the trial used a randomized crossover design, allowing each dog to receive both dosing schedules. The headline result was that once-daily dosing resulted in significantly lower water intake by day 14. At the same time, urine concentration markers, including osmolality and specific gravity, were not significantly different between regimens. Based on the available abstracted information, the study appears focused on adverse-effect expression rather than comparative efficacy for any single disease indication, so the takeaway is primarily about tolerability. (researchgate.net)

That signal is directionally consistent with at least some prior canine literature. BSAVA highlighted a randomized trial in dogs with primary immune-mediated hemolytic anemia in which a single daily prednisolone dose was associated with fewer adverse effects than a twice-daily regimen, including more rapid improvement in polydipsia and lower polyuria scores. Mechanistic work has also reinforced that prednisolone-associated PU/PD is biologically plausible and clinically important, including research linking prednisolone exposure with changes in vasopressin-related pathways. (bsava.com)

Industry and clinician commentary specific to this new 12-dog paper was limited in publicly accessible sources at the time of review, but the broader clinical context is clear. Surveys and observational work suggest steroid side effects are common enough that many pet parents would consider paying more for alternatives with fewer adverse effects. That makes dosing strategy more than a pharmacology detail; it's part of case management, communication, and retention. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinarians, the study offers a modest but useful practice-point: splitting oral prednisolone into twice-daily dosing should not be assumed to reduce PU/PD. In fact, this trial suggests the opposite may be true for water intake over two weeks. In cases where once-daily dosing is therapeutically acceptable, clinicians may have another evidence-based reason to favor the simpler regimen, especially when counseling pet parents about expected side effects and monitoring. Still, the sample size was small, the follow-up was short, and the result should be interpreted cautiously across different diseases, doses, and concurrent medications. (researchgate.net)

The paper also lands in a broader conversation about steroid stewardship in companion animal medicine. If once-daily dosing can preserve efficacy while reducing burden at home, even slightly, that could improve adherence and reduce avoidable callbacks about accidents, thirst, and quality-of-life concerns. But clinicians will still need to individualize decisions based on indication, total dose, disease severity, and the need for rapid immunosuppression versus longer-term taper planning. That inference is supported by the wider literature, but it goes beyond what this single small crossover study alone can prove. (vin.com)

What to watch: The next meaningful development would be larger prospective trials that pair pet parent-reported outcomes with objective urine and water-intake measures, ideally across common prednisolone use cases such as dermatology, immune-mediated disease, and internal medicine. Until then, this study gives clinicians a useful signal, not a final answer. (researchgate.net)